ABSTRACT
Rhabdomyosarcomas are the most common soft-tissue sarcomas, found usually in the younger age group. Histologically, they are subdivided into embryonal, alveolar, pleomorphic and not otherwise specified. They have a heterogenous appearance on imaging with few additional characteristic features based on the subtype. Botryoid variant of embryonal rhabdomyosarcoma commonly involves the genitourinary and the biliary system. They can be multifocal. Most of these lesions have a heterogenous appearance on imaging with areas of necrosis and haemorrhage. On ultrasound, they are polypoidal with cystic areas and are vascular. The lesions are hyperintense on T2 sequences, isointense to the skeletal muscle on T1 sequences and show heterogenous enhancement. Surgery is the mainstay of treatment along with radiotherapy or chemotherapy depending on the site and the stage of the tumour. We report a case of botryoid variant of rhabdomyosarcoma involving the vagina and the urinary bladder.
Subject(s)
Rhabdomyosarcoma, Embryonal , Urinary Bladder Neoplasms , Vaginal Neoplasms , Female , Humans , Magnetic Resonance Imaging , Rhabdomyosarcoma, Embryonal/pathology , Rhabdomyosarcoma, Embryonal/diagnosis , Rhabdomyosarcoma, Embryonal/diagnostic imaging , Rhabdomyosarcoma, Embryonal/surgery , Ultrasonography , Urinary Bladder Neoplasms/diagnostic imaging , Urinary Bladder Neoplasms/pathology , Vaginal Neoplasms/pathology , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/surgery , Vaginal Neoplasms/diagnosis , Child, PreschoolABSTRACT
Vaginal intraepithelial neoplasia (VaIN), a precancerous lesion associated with human papillomavirus (HPV), impacts women's health and quality of life. However, the natural progression of VaIN after hysterectomy remains uncertain, due to its low incidence. The existing literature predominantly consists of single-center retrospective studies lacking robust evidence-based medicine. The management of VaIN after hysterectomy is diverse and controversial, lacking a consensus on the optimal approach. Therefore, it is imperative to investigate the development of VaIN after hysterectomy, emphasizing the importance of accurate diagnosis and effective management strategies.
Subject(s)
Carcinoma in Situ , Hysterectomy , Vaginal Neoplasms , Humans , Female , Vaginal Neoplasms/diagnosis , Vaginal Neoplasms/therapy , Vaginal Neoplasms/surgery , Vaginal Neoplasms/pathology , Vaginal Neoplasms/virology , Carcinoma in Situ/surgery , Carcinoma in Situ/pathology , Carcinoma in Situ/diagnosis , Papillomavirus Infections/diagnosis , Papillomavirus Infections/complicationsABSTRACT
OBJECTIVE: Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterized by a high recurrence rate, usually observed in the lower genital tract of women during their reproductive age. STUDY DESIGN: Seventeen cases of aggressive angiomyxoma confirmed by pathology from January 2007 to December 2021 in Beijing Chao-yang Hospital were included. We collected clinical data and summarized the clinical and immunohistochemical features. RESULTS: All seventeen included patients were females, aged between 23 and 57 years (mean, 37.7 years; median, 42 years). Fourteen patients were newly diagnosed and three were recurrent. The tumors were located in vulva (58.8 %), vagina (23.5 %), buttock (11.8 %), and cervix (5.9 %). The tumors size were 2 to 15 cm in greatest dimension (mean 8 ± 4.4 cm, median 6 cm). Follow-up data was available for nine patients, which ranged from 25 to 124 months (mean, 82 months; median, 80 months). At the end of follow-up, no other recurrence or metastasis was reported. Immunohistochemical analysis showed immunoreactive for estrogen (10/11) and progesterone (8/11) receptor, desmin (6/8), smooth muscle actin (4/10), and vimentin (4/4), S-100 (1/8) and CD34 (1/7). The Ki67 level was less than 5 % in five cases. CONCLUSIONS: AAM is a hormone-sensitive, distinct rare mesenchymal neoplasm with high incidence of local recurrence. Surgery is the preferred treatment, with complete resection being an essential prerequisite for minimizing the risk of recurrence.
Subject(s)
Myxoma , Perineum , Humans , Female , Adult , Myxoma/pathology , Myxoma/surgery , Middle Aged , Retrospective Studies , Perineum/pathology , Young Adult , Pelvic Neoplasms/pathology , Pelvic Neoplasms/surgery , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/surgery , Vulvar Neoplasms/pathology , Vulvar Neoplasms/surgery , Neoplasm Recurrence, Local/pathology , Vaginal Neoplasms/pathology , Vaginal Neoplasms/surgery , Buttocks/pathologyABSTRACT
Background and Objectives: Neoplasms of the vagina are rare and account for 1-2% of all tumors of the female reproductive system. Primary neoplasms of the vagina are most often carcinomas originating from squamous or glandular epithelium. Of the primary glandular tumors, clear cell, endometrioid, and serous adenocarcinomas are the most common types, while mucinous and mesonephric types are very rare. Mucinous adenocarcinoma is histologically subclassified into endocervical and intestinal types. We add to the existing literature another case of an extremely rare gynecological neoplasm-primary vaginal mucinous adenocarcinoma (PVMAC) intestinal type associated with vaginal villous adenoma with high-grade dysplasia. We discuss the clinical, radiological and morphological features of this rare entity. Materials and Methods: We report a case of a 59-year-old woman with PVMAC intestinal type associated with vaginal villous adenoma with high-grade dysplasia. The patient was evaluated with a gynecological exam, and biopsy, curettage and tumor excision were performed. The positron emission tomography-computed tomography (PET/CT) scan, at the level of the pelvis, supported the primary location of the disease. Histological and immunohistochemical methods were applied. Results: The gynecological examination of the vagina revealed an exophytic polypoid mass with a diameter of 3 cm, located on the posterior wall, in the area of introitus vaginae. The PET/CT scan revealed a hypermetabolic malignant formation involving the vagina and anal canal, without evidence of pelvic and inguinal lymphadenopathy, and also, it excluded disease at sites other than the vagina. The histological and immunohistochemical investigations, as well as the clinical and radiological data, lent support to the diagnosis "primary vaginal mucinous adenocarcinoma intestinal type". Conclusions: PVMAC intestinal type is a rare gynecological pathology, which presents a serious challenge for oncogynecologists, radiologists and pathologists.
Subject(s)
Adenocarcinoma, Mucinous , Vaginal Neoplasms , Humans , Female , Middle Aged , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/diagnostic imaging , Adenocarcinoma, Mucinous/diagnosis , Adenocarcinoma, Mucinous/surgery , Vaginal Neoplasms/pathology , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/surgery , Vaginal Neoplasms/diagnosis , Positron Emission Tomography Computed Tomography/methods , Vagina/pathology , Vagina/diagnostic imagingABSTRACT
PURPOSE: This study aimed to evaluate the clinical efficacy and safety of argon plasma coagulation (APC) therapy and interferon therapy in patients with grade I and II vaginal intraepithelial neoplasia (VaIN). METHODS: A total of 112 patients with VaIN were diagnosed via colposcopy-induced biopsy and classified into the APC group (n = 77) and interferon group (n = 35). Clinical data including age, grade, symptoms, historical or concomitant neoplasia of the lower genital tract, indications for hysterectomy, pregnancy history, cytology, human papillomavirus (HPV) subtype, treatment modalities, and clinical outcomes were analyzed, retrospectively. Complications and clinical outcomes were assessed at 6- and 12-month follow-ups. RESULTS: There was no significant difference in the HPV clearance rate between the APC (53.42%) and interferon (33.33%) groups at 6 months after treatment. However, the 12-month follow-up of the APC group showed a significantly higher HPV clearance rate as compared to the interferon group (87.67% vs. 51.52%, P < 0.05). The APC group exhibited a significantly higher cure rate (79.22% vs. 40.0%) and lower persistence rate (12.99% vs. 37.14%) than the interferon group (P < 0.05). Adverse reaction analysis revealed that the primary reaction in the APC group was vaginal drainage, in contrast to the increased vaginal discharge in the interferon group; though the difference was significant (68.83% vs. 28.57%, P < 0.05), no serious complications were observed. CONCLUSIONS: Treatment with APC is a safe and more effective procedure against VaIN I and II, compared to interferon. APC may serve as a viable alternative to other physiotherapies.
Subject(s)
Argon Plasma Coagulation , Carcinoma in Situ , Vaginal Neoplasms , Humans , Female , Retrospective Studies , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/virology , Vaginal Neoplasms/surgery , Vaginal Neoplasms/therapy , Adult , Middle Aged , Carcinoma in Situ/drug therapy , Carcinoma in Situ/surgery , Carcinoma in Situ/therapy , Carcinoma in Situ/virology , Carcinoma in Situ/pathology , Papillomavirus Infections/complications , Papillomavirus Infections/therapy , Treatment Outcome , Interferons/therapeutic use , Colposcopy , Combined Modality TherapySubject(s)
Diagnostic Errors , Hutchinson's Melanotic Freckle , Vaginal Neoplasms , Humans , Female , Hutchinson's Melanotic Freckle/pathology , Hutchinson's Melanotic Freckle/diagnosis , Vaginal Neoplasms/diagnosis , Vaginal Neoplasms/pathology , Vaginal Neoplasms/surgery , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , AgedSubject(s)
Adenocarcinoma , Vaginal Neoplasms , Female , Humans , Neoadjuvant Therapy , Vagina , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/surgery , Vaginal Neoplasms/pathology , Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Adenocarcinoma/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Neoplasm StagingABSTRACT
PURPOSE: This systematic review aims to provide a data synthesis about the risk of neovaginal cancer in women with Müllerian anomalies and to investigate the association between the adopted reconstructive technique and the cancer histotype. METHODS: PubMed, MEDLINE, Embase, Scopus, ClinicalTrials.gov and Web of Science databases were searched from inception to March 1st, 2023. Studies were included if: (1) only women affected by Müllerian malformations were included, (2) the congenital defect and the vaginoplasty technique were clearly reported, (3) the type of malignancy was specified. RESULTS: Literature search yielded 18 cases of squamous cell carcinoma and two cases of vaginal intraepithelial neoplasia 3 (VAIN 3). Of these, 3 had been operated on according to the Wharton technique, 8 according to the McIndoe technique, 3 with a split-skin graft vaginoplasty, 2 according to the Davydov technique, 2 with a simple cleavage technique, 1 according to the Vecchietti technique and 1 with a bladder flap vaginoplasty. A total of 17 cases of adenocarcinoma and 1 case of high-grade polypoid dysplasia were also described. Of these, 15 had undergone intestinal vaginoplasty, 1 had been operated on according to the McIndoe technique and 1 had undergone non-surgical vaginoplasty. Finally, 1 case of verrucous carcinoma in a woman who had undergone a split-skin graft vaginoplasty, was reported. CONCLUSION: Although rare, neovaginal carcinoma is a definite risk after vaginal reconstruction, regardless of the adopted technique. Gynaecologic visits including the speculum examination, the HPV DNA and/or the Pap smear tests should be scheduled on an annual basis.
Subject(s)
46, XX Disorders of Sex Development , Adenocarcinoma , Carcinoma, Squamous Cell , Congenital Abnormalities , Plastic Surgery Procedures , Vaginal Neoplasms , Humans , Female , Vagina/pathology , Vaginal Neoplasms/surgery , Vaginal Neoplasms/pathology , Carcinoma, Squamous Cell/pathology , Adenocarcinoma/pathology , Mullerian Ducts/surgery , Mullerian Ducts/abnormalities , 46, XX Disorders of Sex Development/surgery , Congenital Abnormalities/surgery , Congenital Abnormalities/pathology , Gynecologic Surgical Procedures/methods , Treatment OutcomeABSTRACT
Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms originating from or differentiating into nerve sheaths of peripheral nerves. Vaginal origin is rare, with only six vaginal primary cases reported to date. A 55-year-old woman presented to our hospital with a 7 cm vulvar mass. Tumor biopsy results were suspicious of sarcoma, and pelvic magnetic resonance imaging and hysterofiberscopy showed that the tumor originated from the lower vagina. The mass was transvaginally excised, and histological examination confirmed the diagnosis of a vaginal MPNST with negative surgical margins. The patient underwent radiotherapy because the risk of recurrence was high, owing to the large tumor size and high mitotic index. The patient remained recurrence-free for 1 year after the primary treatment. This is the first case of a high-risk vaginal MPNST that avoided early disease recurrence with additional radiotherapy after complete tumor resection.
Subject(s)
Nerve Sheath Neoplasms , Radiotherapy, Adjuvant , Vaginal Neoplasms , Female , Humans , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Neoplasm Recurrence, Local/surgery , Nerve Sheath Neoplasms/radiotherapy , Nerve Sheath Neoplasms/surgery , Nerve Sheath Neoplasms/diagnosis , Neurofibrosarcoma/complications , Vaginal Neoplasms/diagnosis , Vaginal Neoplasms/radiotherapy , Vaginal Neoplasms/surgeryABSTRACT
INTRODUCTION: Primary vaginal malignant melanoma is a rare gynecological malignant tumor with high malignancy and poor prognosis. Because of its insidious incidence, it is generally diagnosed in the late stage, and the 5-year survival rate is only 5% to 25%. Due to the rarity of this disease and the limited number of related cases reported in the literature, there is currently no unified standard for its diagnosis and treatment. Therefore, the treatment of this disease has always been a difficult problem in clinical practice. PATIENT CONCERNS: A 56-year-old woman was admitted to our hospital with discomfort in the lower abdomen. DIAGNOSIS: The final diagnosis of this patient was vaginal malignant melanoma (T4N1M0). INTERVENTIONS: The patient underwent extensive hysterectomy, bilateral adnexectomy, pelvic lymph node resection, and total vaginectomy. Following the surgery, the patient received adjuvant chemotherapy. OUTCOMES: The patient was followed up regularly. No recurrence or metastasis has been reported to date. CONCLUSION: The treatment of primary vaginal malignant melanoma is still dominated by surgery, while radiotherapy and chemotherapy are controversial. Immunotherapy and targeted therapy highlight certain advantages in advanced patients, which still need to be verified by large sample studies, We provide a case of postoperative adjuvant chemotherapy for vaginal malignant melanoma. So far, no signs of disease recurrence have been found. As the price of chemotherapy drugs decreases, it is economically convenient and acceptable for most patients, but its effectiveness needs to be observed in large-scale clinical trials.
Subject(s)
Melanoma , Vaginal Neoplasms , Female , Humans , Middle Aged , Lymph Node Excision , Lymph Nodes/pathology , Melanoma/diagnosis , Melanoma/surgery , Neoplasm Recurrence, Local/surgery , Vaginal Neoplasms/surgery , Vaginal Neoplasms/pathologyABSTRACT
A woman in her 90s with chronic uterine prolapse presented with abdominal pain and a vaginal mass. The patient had generalised peritonitis and a strangulated bowel obstruction originating from a perforated posterior vagina. We performed partial intestinal resection and a total hysterectomy, including excision of the perforation of the vaginal site and the adnexa. The patient died on postoperative day 8 due to worsening systemic sepsis. The pathological diagnosis revealed an invasive carcinoma in the perforated area of the vagina. Obstetric factors are the most frequent cause of female genital tract perforation, and chronic uterine prolapse is associated with this condition; however, vaginal cancer has never been reported as a cause of perforation. Therefore, close collaboration in gynaecology should be considered to investigate whether vaginal perforation and uterine prolapse are related to cancer.
Subject(s)
Intestinal Obstruction , Uterine Prolapse , Vaginal Neoplasms , Female , Humans , Hysterectomy/adverse effects , Intestinal Obstruction/diagnostic imaging , Intestinal Obstruction/etiology , Intestinal Obstruction/surgery , Uterine Prolapse/complications , Uterine Prolapse/surgery , Vagina/surgery , Vaginal Neoplasms/surgery , Aged, 80 and overABSTRACT
INTRODUCTION AND HYPOTHESIS: Vaginal leiomyomas are uncommon benign tumors of the genital district that appear as a circumscribed, mobile, and nontender mass along the vaginal tube. The gold standard of vaginal leiomyoma management is surgical treatment. We aimed to present a clinical case of vaginal leiomyoma successfully treated throughout a transvaginal excision and layered repair. METHODS: A 44-year-old woman was referred to our division for vaginal bulging symptoms and dyspareunia. Clinical examination revealed a 4-5 cm hard bulging mass in the anterior vaginal wall, below the urethra, compatible with vaginal leiomyoma. After proper counseling, the patient was admitted to transvaginal leiomyoma excision plus primary layered repair. RESULTS: No surgical complications were observed. The indwelling catheter was removed the day after the surgery. The patient was successfully discharged home on postoperative day 1. The patient is currently asymptomatic and there are no signs of recurrence. CONCLUSION: The procedure was successful in obtaining anatomical repair and relieving symptoms. This approach represents a valid procedure for the surgical management of this uncommon condition.
Subject(s)
Leiomyoma , Vaginal Neoplasms , Female , Humans , Adult , Leiomyoma/complications , Leiomyoma/surgery , Leiomyoma/diagnosis , Urethra/pathology , Vaginal Neoplasms/surgery , Urinary Bladder/pathologyABSTRACT
Primary endometrioid adenocarcinoma of the rectovaginal septum is rare. Its pathogenesis is not clear and there is no standard treatment. One patient with endometrioid adenocarcinoma of the rectovaginal septum arising from deep infiltrative endometriosis was admitted to Qingdao Municipal Hospital. The patient presented with incessant menstruation and abdominal distension. She had bilateral ovarian endometriotic cystectomy 6 years ago. Imaging findings suggested a pelvic mass which might invade the rectovaginal septum. Pathological results of primary surgery confirmed endometrioid carcinoma of the pelvic mass arising from the rectovaginal septum. Then she had a comprehensive staged surgery. Postoperative chemotherapy was given 6 times. No recurrence or metastasis was found during the 2-year follow-up. The possibility of deep infiltrating endometriosis and its malignant transformation should be considered in the differential diagnosis of a new extragonadal pelvic lesion in a patient with a history of endometriosis, which would avoid misdiagnosis and missed diagnosis.
Subject(s)
Carcinoma, Endometrioid , Rectal Neoplasms , Vaginal Neoplasms , Female , Humans , Carcinoma, Endometrioid/diagnostic imaging , Carcinoma, Endometrioid/drug therapy , Carcinoma, Endometrioid/pathology , Carcinoma, Endometrioid/surgery , Endometriosis/pathology , Endometriosis/surgery , Rectal Neoplasms/diagnostic imaging , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/pathology , Vaginal Neoplasms/surgery , Diagnosis, DifferentialABSTRACT
The article presents a rare clinical observation of a vaginal tumor detected during pregnancy, which prevented delivery through the natural birth canal and caused a cesarean section at full term. According to the primary biopsy at 34 weeks, neurofibroma was diagnosed. In the postpartum period, due to profuse bloody discharge, the patient was admitted to the Moscow Regional Research Institute of Obstetrics and Gynecology for surgical treatment, where, according to the results of a morphological study of the removed tumor, vaginal leiomyosarcoma was diagnosed.
Subject(s)
Leiomyosarcoma , Vaginal Neoplasms , Pregnancy , Female , Humans , Cesarean Section , Delivery, Obstetric/methods , Vaginal Neoplasms/diagnosis , Vaginal Neoplasms/surgery , Leiomyosarcoma/diagnosis , Leiomyosarcoma/surgery , MoscowABSTRACT
OBJECTIVE: As vulvar and vaginal cancers are rare malignancies, treatment is extrapolated from the cervical cancer field. Further studies are necessary to evaluate whether surgery, radiotherapy (RT), or combined chemoRT is most beneficial. METHODS: A retrospective chart review was conducted on patients diagnosed with vulvar or vaginal cancer in 2000-2017. Descriptive statistics was used to summarize demographic factors. Kaplan-Meier curves, log-rank tests, multivariate analysis with hazard ratios (HR) were conducted to compare survival outcomes, including overall survival (OS), disease-free survival, and cancer-specific survival, between surgery, RT, and chemoRT. RESULTS: This study included 688 patients with either vulvar (n = 560, 81%) or vaginal cancer (n = 128, 19%). Median age of diagnosis was 68 (27-98) years. In multivariate survival analysis, vulvar cancer was associated with more likelihood of death (HR: 1.50, p = 0.042) compared to vaginal cancer. For patients who received definitive RT, median OS was 63.8 months with concurrent chemotherapy vs. 46.3 months without for vulvar cancer (p = 0.75); for vaginal, median OS 100.4 with chemotherapy vs. 66.6 months without (p = 0.31). For vulvar cancer patients who received RT (n = 224), adding chemotherapy (n = 100) was not associated with statistically significant OS improvement (HR: 0.989, p = 0.957). Similarly, vaginal cancer patients who received chemoRT (n = 51) did not have significant OS benefit (HR: 0.720, p = 0.331) over patients who received RT (n = 49). CONCLUSIONS: In this retrospective study, chemoRT was not associated with significant improvements in survival compared to RT in vulvar or vaginal cancer. Future studies investigating novel therapies to treat these cancers are needed to improve patient outcomes.
Subject(s)
Vaginal Neoplasms , Vulvar Neoplasms , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/radiotherapy , Vaginal Neoplasms/surgery , Vulvar Neoplasms/drug therapy , Vulvar Neoplasms/radiotherapy , Vulvar Neoplasms/surgery , Humans , Female , British Columbia , Adult , Middle Aged , Aged , Aged, 80 and over , Disease-Free SurvivalSubject(s)
Adenocarcinoma , Vaginal Diseases , Vaginal Neoplasms , Female , Humans , Stomach , Hyperplasia , Vaginal Neoplasms/surgeryABSTRACT
Vaginal intraepithelial neoplasia is an uncommon Human Papilloma Virus-related premalignant lesion of the lower genital tract. There is still no consensus regarding its management. Therapeutic modalities include observation, laser ablation, topical agents, radiation and surgical approach. Due to the current increasing adherence to minimally invasive therapies the aim of this study is to identify and characterize non-excisional treatment modalities. Expectant management is the first therapeutical option in low-grade lesions management. Up to 81% of lesions through an expectant approach regressed spontaneously and most of them were low-grade lesions. In contrast, high-grade lesions, due to its higher potential to invasion progression and low regression rate, require treatment, which should be selected depending on its characteristics and the patient's preference. Laser ablation is suitable for multifocal lesions in sexually active young women with a cure rate up to 90% and recurrence rate up to 6.3%. Brachytherapy can be 71.4%-90% efficient with a maximum of 5.8% and 20% of persistence rate and recurrence rate, respectively. However, due to its toxicity, it should be reserved for selected cases only. Topical modalities for multifocal lesions, such as Imiquimod 5% and 5-Flouorouracil, have a good therapeutic effect, low pharmacological morbidity, and 25%-98% cure rate, 11.1%-75% persistence rate and 5.6%-94.4% recurrence rate.